Protalix BioTherapeutics (NYSE:PLX) Announces Quarterly Earnings Results

Protalix BioTherapeutics (NYSE:PLXGet Free Report) released its earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, reports. The company had revenue of $3.75 million for the quarter. Protalix BioTherapeutics had a net margin of 11.48% and a return on equity of 18.54%.

Protalix BioTherapeutics Stock Performance

Shares of NYSE PLX opened at $1.10 on Monday. The firm has a market capitalization of $80.65 million, a price-to-earnings ratio of 27.50 and a beta of 0.90. The stock has a 50 day moving average price of $1.26 and a 200 day moving average price of $1.45. Protalix BioTherapeutics has a 52-week low of $1.03 and a 52-week high of $2.88.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Protalix BioTherapeutics from a “buy” rating to a “hold” rating in a report on Friday, March 15th.

Read Our Latest Analysis on PLX

Institutional Trading of Protalix BioTherapeutics

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in Protalix BioTherapeutics by 12.8% in the third quarter. Bank of New York Mellon Corp now owns 165,680 shares of the company’s stock worth $275,000 after buying an additional 18,760 shares in the last quarter. SG Americas Securities LLC bought a new position in Protalix BioTherapeutics in the third quarter worth approximately $50,000. Barclays PLC raised its stake in Protalix BioTherapeutics by 251.6% in the third quarter. Barclays PLC now owns 46,511 shares of the company’s stock worth $77,000 after buying an additional 33,281 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Protalix BioTherapeutics by 45.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 167,536 shares of the company’s stock worth $278,000 after buying an additional 51,997 shares in the last quarter. Finally, Bailard Inc. bought a new position in Protalix BioTherapeutics in the fourth quarter worth approximately $121,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

(Get Free Report)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

Read More

Earnings History for Protalix BioTherapeutics (NYSE:PLX)

Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.